From: Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
High-dose glucocorticoids (n = 8) | Low-dose glucocorticoids (n = 353) | No glucocorticoids (n = 302) | |
---|---|---|---|
Male | 2 (25.0) | 189 (53.5) | 165 (54.6) |
Age, years | 61.8 (4.2) | 65.5 (10.0) | 66.2 (9.6) |
Former or current smoker | 3 (37.5) | 173 (49.0) | 162 (53.6) |
ILD diagnosis | |||
Hypersensitivity pneumonitis | 5 (62.5) | 96 (27.2) | 72 (23.8) |
Autoimmune ILDsa | 1 (12.5) | 114 (32.3) | 55 (18.2) |
iNSIP | 0 | 65 (18.4) | 60 (19.9) |
Unclassifiable IIP | 2 (25.0) | 41 (11.6) | 71 (23.5) |
Other ILDsb | 0 | 37 (10.5) | 44 (14.6) |
FVC, mL | 1744 (546) | 2287 (696) | 2397 (771) |
FVC, % predicted | 53.8 (6.9) | 67.4 (14.9) | 71.2 (16.2) |
DLco, % predicted | 44.4 (9.1) | 44.4 (12.6) | 48.2 (14.6) |